BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21673355)

  • 1. Cervical cancer prevention through cytologic and human papillomavirus DNA screening in Hong Kong Chinese women.
    Wu J
    Hong Kong Med J; 2011 Jun; 17(3 Suppl 3):20-4. PubMed ID: 21673355
    [No Abstract]   [Full Text] [Related]  

  • 2. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of HPV testing on cervical cancer screening].
    Li G
    Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):241-5. PubMed ID: 26080933
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Lynge E; Rebolj M
    J Natl Cancer Inst; 2010 May; 102(10):739; author reply 739-40. PubMed ID: 20360534
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
    Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
    BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menstrual pad, a cervical cancer screening tool, a population-based study in rural India.
    Budukh A; Palayekar V; Maheshwari A; Deodhar K; Purwar P; Bagal S; Vadigoppula A; Lokhande M; Panse N; Dikshit R; Badwe R
    Eur J Cancer Prev; 2018 Nov; 27(6):546-552. PubMed ID: 28704213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
    Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
    J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial.
    Broberg G; Jonasson JM; Ellis J; Gyrd-Hansen D; Anjemark B; Glantz A; Söderberg L; Ryd ML; Holtenman M; Milsom I; Strander B
    Int J Cancer; 2013 Jul; 133(1):164-71. PubMed ID: 23233356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower cost strategies for triage of human papillomavirus DNA-positive women.
    Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical testing beyond the screening target age - A register-based cohort study from Finland.
    Keltto N; Leivonen A; Pankakoski M; Sarkeala T; Heinävaara S; Anttila A
    Gynecol Oncol; 2021 Aug; 162(2):315-321. PubMed ID: 34074539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada.
    Healey SM; Aronson KJ; Mao Y; Schlecht NF; Mery LS; Ferenczy A; Franco EL
    Sex Transm Dis; 2001 Dec; 28(12):694-700. PubMed ID: 11725224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China.
    Zhao FH; Jeronimo J; Qiao YL; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Cancer Prev Res (Phila); 2013 Sep; 6(9):938-48. PubMed ID: 23878179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta.
    Campos NG; Scarinci IC; Tucker L; Peral S; Li Y; Regan MC; Sy S; Castle PE; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1114-1121. PubMed ID: 33771846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.
    Schiffman M; Herrero R; Hildesheim A; Sherman ME; Bratti M; Wacholder S; Alfaro M; Hutchinson M; Morales J; Greenberg MD; Lorincz AT
    JAMA; 2000 Jan; 283(1):87-93. PubMed ID: 10632285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.